64% of large firms say GLP-1 drug coverage moderately or significantly impacted their prescription drug spending Similar to the findings on use, 43% of firms with 1,000 to 4,999 workers, and 66% of firms with 5,000 or more workers, say that covering GLP-1 agonists for weight loss had a significant impact on the health plans prescription drug spending
Muscle tissue supports resting metabolic rate and long-term weight maintenance
Adding retatrutide 5 to 10 BPM on top of that pushes the total increase into a range where healthy individuals might notice uncomfortable cardiovascular symptoms
The development of small molecule GLP-1RAs provides a new option for obese and T2D individuals who have been undergoing long-term injection therapy
Even a single reuse dulls the needle, making it more likely to tear tissue instead of piercing cleanly
The primary outcome was a composite measure that included psychiatric hospitalizations, extended sick leave for psychiatric reasons, hospitalization due to self-harm, or death by suicide